biote vs Lifevantage
BTMD and LFVN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BTMD and LFVN compare
Lifevantage is the larger company, worth 1.7 times as much as biote ($59.9M against $35.6M).
On earnings, biote is cheaper: it trades at 9.9× trailing earnings, against 11.9× for Lifevantage.
biote grew revenue faster over the last twelve months (−7.8% versus −20.1% for Lifevantage).
biote keeps more of each dollar of sales as profit, with a net margin of 3.2% compared with 2.8% at Lifevantage.
Lifevantage pays a dividend yielding 4.0%; biote does not pay one.
Lifevantage scores higher on the StockData Score (20 against 8 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BTMD | LFVN |
|---|---|---|
| Size and price | ||
| Market cap | $35.6M | $59.9M |
| Share price | $0.990 | $4.78 |
| Change, 1 year | −60.7% | −27.8% |
| Change, 5 years | −89.8% | −29.2% |
| Beta (5Y) | 1.96 | 0.59 |
| Employees | 223 | 223 |
| StockData Score | ||
| Total score | 8 | 20 (better) |
| Valuation score | 4 | 6 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 9.9× (better) | 11.9× |
| P/S | 0.2× (better) | 0.3× |
| P/B | – | 1.8× |
| EV/EBITDA | 8.3× | 5.1× (better) |
| P/FCF | 1.8× (better) | 9.0× |
| PEG | – | 0.46 |
| FCF yield | 55.9% (better) | 11.1% |
| Fair value | $3.20 | $8.48 |
| Margin of safety | 69.0% (better) | 43.6% |
| Growth | ||
| Revenue growth (TTM) | −7.8% (better) | −20.1% |
| Revenue growth, 5Y average | – | −3.7% |
| Net income growth (TTM) | −81.3% | −48.3% (better) |
| EPS growth (TTM) | −88.9% | −46.7% (better) |
| EPS growth, 5Y average | – | −15.0% |
| Profitability | ||
| Gross margin | 68.6% | 77.6% (better) |
| Operating margin | 8.0% (better) | 3.3% |
| Net margin | 3.2% (better) | 2.8% |
| FCF margin | 10.8% (better) | 3.7% |
| Return on equity | – | 14.9% |
| Return on invested capital | 45.7% (better) | 30.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 5.93 | – |
| Current ratio | 1.43 | 1.89 (better) |
| Altman Z-score | 1.87 | 2.54 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 4.0% |
| Payout ratio | 19.9% | 46.2% |
| Years of dividend growth | – | 1 |
| Buyback yield | – | 3.4% |
| Shareholder yield | 0.00% | 7.4% (better) |
| Ownership | ||
| Held by institutions | 36.6% | 47.2% |
| Held by insiders | 23.3% | 27.8% |
| Insider net buying, 12 months | $202K (better) | $6.0K |
| Short interest, % of float | 3.1% | 10.0% |
Go deeper
- BTMD stock overview
- BTMD income statement
- BTMD valuation and score
- LFVN stock overview
- LFVN income statement
- LFVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.